DelveInsight’s “Cholestatic Pruritus Pipeline Insights, 2021” report provides detailed insights into the Cholestatic Pruritus market’s current clinical development status and growth prospects. The disease summary and Cholestatic Pruritus therapy guidelines are included in a complete description of the Cholestatic Pruritus pipeline environment.
Some Key Highlights from the Cholestatic Pruritus Pipeline Report
Mirum Pharmaceuticals, GlaxoSmithKline, CymaBay Therapeutics, Cara Therapeutics, Escient Pharmaceuticals are among the notable companies who are testing their drug candidates in the Cholestatic Pruritus treatment market.
Pipeline therapy for Cholestatic Pruritus such as LUM001 (Mirum Pharmaceuticals) is in the pre-registration phase.
Some pipeline therapies for Cholestatic Pruritus such as GSK2330672 and Seladelpar are in the Phase III of development while pipeline therapy like Korsuva is in Phase II of clinical trials.
Pipeline therapy such as EP 547 is still in the early stage of development i.e. Phase I of clinical trials for Cholestatic Pruritus.
For more information request sample @ Cholestatic Pruritus Pipeline Insights
Cholestatic Pruritus: Disease Overview
Cholestasis is a reduction in bile flow caused by decreased hepatocyte secretion or obstruction of bile flow through intra- or extrahepatic bile ducts. This bile secretion problem occurs somewhere between the liver cells that make bile and the duodenum (the first segment of the small intestine).
Furthermore, both intrahepatic cholestasis and extrahepatic biliary blockage can cause pruritus. Primary Biliary Cirrhosis (PBC), cholestasis during pregnancy (pruritus gravidarum), drug-induced cholestasis, and viral hepatitis are all intrahepatic cholestasis processes linked to pruritus.
Cholestatic Pruritus Pipeline Analysis: Drug Profile
GSK2330672 is a human IBAT selective inhibitor that is designed to be a non-absorbable drug that is limited to the gastrointestinal (GI) tract. The company has completed Phase II of clinical development, and phase III trials are currently underway.
Research and Development in the Cholestatic Pruritus Pipeline Landscape
NCT04167358: GlaxoSmithKline began a study called “Long-term Safety and Tolerability Study with Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis” in July 2020. The trial is presently recruiting volunteers, with a target participation of 75 people, and it is set to end in December 2024.
Cholestatic Pruritus Pipeline Therapies and Key Companies
LUM001: Mirum Pharmaceuticals
Seladelpar: CymaBay Therapeutics
Korsuva: Cara Therapeutics
EP 547: Escient Pharmaceuticals
Learn more about Cholestatic Pruritus @ Cholestatic Pruritus Pipeline Therapies and Key Companies
Cholestatic Pruritus Therapeutics Assessment
By Product Type
By Route of Administration
By Molecule Type
Stem Cell Therapy
By Mechanism of Action
Multiple Kinase Inhibitors
Scope of the Report
Cholestatic Pruritus Key Players: Mirum Pharmaceuticals, GlaxoSmithKline, CymaBay Therapeutics, Cara Therapeutics, Escient Pharmaceuticals, among others
Cholestatic Pruritus Pipeline Therapies: LUM001, GSK2330672, Seladelpar, Korsuva, EP 547, and others
Table of Contents
Cholestatic Pruritus: Overview
Cholestatic Pruritus- Analytical Perspective In-depth Commercial Assessment
Cholestatic Pruritus Pipeline Therapeutics
Cholestatic Pruritus Late Stage Products (Pre-Registration)
Cholestatic Pruritus Late Stage Products (Phase III)
Cholestatic Pruritus Mid Stage Products (Phase II)
Cholestatic Pruritus Early Stage Products (Phase I)
Cholestatic Pruritus Therapeutic Assessment
Cholestatic Pruritus Inactive Products
Cholestatic Pruritus Company-University Collaborations (Licensing/Partnering) Analysis
Cholestatic Pruritus Key Companies
Cholestatic Pruritus Key Products
Cholestatic Pruritus- Unmet Needs
Cholestatic Pruritus- Market Drivers and Barriers
Cholestatic Pruritus- Future Perspectives and Conclusion
Cholestatic Pruritus Analyst Views
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
Key questions answered in the Cholestatic Pruritus Pipeline Report
What are the treatment options for Cholestatic Pruritus?
How many companies are working on Cholestatic Pruritus treatments?
Which of these companies’ medicines is the most widely used?
How many Cholestatic Pruritus medicines has each company generated in total?
How many innovative therapies for Cholestatic Pruritus are being developed in the early, mid, and late stages?
How many of the drugs under development can be used alone or in combination with other treatments?
What are the most important industry-industry and industry-academy collaborations, mergers and acquisitions, and licencing practises that will affect Cholestatic Pruritus?
Primary Biliary Cholangitis Pipeline Insights
Get comprehensive analysis of Primary Biliary Cholangitis pipeline therapies and key companies including Genfit, CymaBay Therapeutics, Mirum Pharmaceuticals, Gilead Sciences, Eli Lilly and Company, Future Medicine, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States